SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001479290-23-000093
Filing Date
2023-08-08
Accepted
2023-08-08 16:34:36
Documents
77
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rvnc-20230630.htm   iXBRL 10-Q 1537101
2 EX-31.1 rvncq223exhibit311.htm EX-31.1 8672
3 EX-31.2 rvncq223exhibit312.htm EX-31.2 8684
4 EX-32.1 rvncq223exhibit321.htm EX-32.1 6379
5 EX-32.2 rvncq223exhibit322.htm EX-32.2 6432
  Complete submission text file 0001479290-23-000093.txt   8276302

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20230630.xsd EX-101.SCH 57794
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20230630_cal.xml EX-101.CAL 106836
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20230630_def.xml EX-101.DEF 259869
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20230630_lab.xml EX-101.LAB 741016
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20230630_pre.xml EX-101.PRE 471389
71 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20230630_htm.xml XML 1334517
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36297 | Film No.: 231152002
SIC: 2834 Pharmaceutical Preparations